Senses Disorder TRIZ Cases

A cationic ophthalmic oil-in-water emulsion encapsulates prostaglandins in an oily core to enhance chemical stability and bioavailability.

Indolin-2-one derivatives target NMDA glycine sites and ENT1 transporters to reverse hyperlocomotion, addressing negative symptoms of schizophrenia.

Targeting IL-7 and IL-15 signaling reduces Th17 proliferation, avoiding corticosteroid side effects like raised intraocular pressure.

Silencing connexin 43 via RNA interference lowers intraocular pressure while avoiding systemic side effects of conventional glaucoma drugs.

Smurf-1 inhibitors halt pulmonary vascular remodeling by blocking ubiquitin ligase activity.

Purified yatein from Juniperus chinensis suppresses pathological angiogenesis while preserving normal physiological processes through selective dosing.

Anion exchange chromatography isolates Factor H from plasma Fraction II+III precipitates.

Substituted triazoles activate TRPM8 channels to increase tear and mucous secretion, addressing insufficient channel activation in existing agonists.

Sequential VEGF antagonist dosing reduces injection frequency while maintaining therapeutic efficacy.

Formula I compounds inhibit porcupine enzyme activity to regulate WNT signaling pathways, addressing variable potency across cell lines.

Boron-containing small molecules inhibit phosphodiesterase 4 enzyme activity to reduce pro-inflammatory cytokine expression.

Segmented FcRn binding motifs replace bulky fusion domains to extend in vivo half-life while preserving tissue penetration and reducing immunoreactivity.

A buffered artificial tear composition with methylglyoxal and Manuka honey reduces discomfort while avoiding the stinging caused by conventional preservatives.

PEG conjugation prevents aggregation at high concentrations, enabling stable formulations with prolonged ocular residence.

Achiral benzothiazole-benzylamides inhibit casein kinase 1, eliminating racemic mixture toxicity and simplifying clinical development.

Bicyclic heterocyclyl derivatives with thiadiazolyl groups enhance therapeutic efficacy and specificity in cancer treatment.

Segmented siRNA sequences inhibit HSP47 expression, addressing fibrotic disease bottlenecks.

Crosslinkable tetraarylbenzene compounds serve as host materials in organic light-emitting diodes.

Photoreceptor precursors expressing optogenetic inhibitors restore visual function by mimicking healthy cell responses.

Electron-withdrawing substituents at position 5 enhance potency of adenosine A2A receptor antagonism.

New heterocyclic derivatives improve metabolic stability and specificity while maintaining potent Hsp90 inhibition.

A hydrophobic prodrug contact lens provides sustained release of therapeutic agents directly to the ocular surface.

Controlled release formulations deliver auris sensory cell modulators locally to the inner ear, reducing systemic toxicity while maintaining drug efficacy.

Topical PAI-2 fusion proteins inhibit urokinase plasminogen activator to prevent corneal tissue destruction while preserving wound healing cell migration.

Hyaluronic acid graft polymers form spontaneous nanoparticles to resolve rapid enzymatic degradation while maintaining biocompatibility.

A trans-splicing ribozyme system joins wild-type rhodopsin transcripts to mutant targets.

Combining muscarinic agonists with brimonidine extends pinhole effect duration while avoiding ciliary muscle spasm side effects.

Targeting host dihydroorotate dehydrogenase bypasses viral mutation resistance, offering potent antiviral activity with minimal cytotoxicity.

Uses myo-inositol and probiotics to improve insulin sensitivity without drug side effects.

A bioerodible polymer implant sustains mometasone furoate release into the vitreous chamber through controlled diffusion and erosion mechanisms.

Optimized promoters and regulatory elements boost EGF secretion to enhance wound healing efficacy.

Oral Angio-3 peptide attenuates retinal angiogenesis, bypassing injection resistance.

Combining pilocarpine with phenylephrine restores accommodative function without invasive surgery, enabling clear near vision while preserving distance sight.

Oral interferon-alpha reduces invasive injection needs and side effects while treating chronic external otitis in dogs and cats.

Administering specific stem cells inhibits excessive neovascularization, preventing tumor growth and vision loss in angiogenesis-related disorders.

Engineering the toxin binding domain increases receptor affinity, reducing systemic dispersal and preventing unintended muscle paralysis.

Non-peptidic renin inhibitors resolve the contradiction between in vitro potency and oral bioavailability while lowering production costs.

Topical high molecular weight hyaluronic acid fluid stabilizes the tear film and reduces friction on the ocular surface.

Bisamide derivatives selectively bind zinc and copper ions to treat diseases while minimizing systemic toxicity.

Histidine or citrate buffers stabilize soluble Fc receptors above 50 mg/mL, preventing precipitation and viscosity issues during storage.

A minocycline topical suspension treats meibomian gland dysfunction while minimizing systemic exposure and local irritation.

Direct ocular administration of calcium channel blockers increases retinal blood supply, resolving insufficient local drug concentration from oral routes.

Liquid NSAID salt mixing with molten lozenges stabilizes flavor variety without compromising structural integrity.

GelMA and HAMA crosslink to join corneal tissue, resolving the trade-off between adhesive strength and biocompatibility.

Neutral endopeptidase inhibitors prevent enzymatic breakdown of atrial natriuretic peptide, extending its therapeutic duration for cardiovascular treatment.

Amino acid sequences encode human leukocyte antigen G via adeno-associated virus vectors to modulate ocular immune responses.